Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.
Identifieur interne : 000066 ( Main/Exploration ); précédent : 000065; suivant : 000067Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.
Auteurs : Tina Devries [États-Unis] ; Angela Dentiste [États-Unis] ; Clifford Di Lea [États-Unis] ; Vincent Pichette [Canada] ; David Jacobs [États-Unis]Source :
- CNS drugs [ 1179-1934 ] ; 2019.
Descripteurs français
- KwdFr :
- Administration par voie orale (MeSH), Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Amantadine (administration et posologie), Amantadine (pharmacocinétique), Amantadine (usage thérapeutique), Comprimés (administration et posologie), Comprimés (pharmacocinétique), Comprimés (usage thérapeutique), Femelle (MeSH), Humains (MeSH), Insuffisance rénale (métabolisme), Jeune adulte (MeSH), Maladie de Parkinson (traitement médicamenteux), Mâle (MeSH), Préparations à action retardée (administration et posologie), Préparations à action retardée (pharmacocinétique), Préparations à action retardée (usage thérapeutique), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH).
- MESH :
- administration et posologie : Amantadine, Comprimés, Préparations à action retardée.
- métabolisme : Insuffisance rénale.
- pharmacocinétique : Amantadine, Comprimés, Préparations à action retardée.
- traitement médicamenteux : Maladie de Parkinson.
- usage thérapeutique : Amantadine, Comprimés, Préparations à action retardée.
- Administration par voie orale, Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Administration, Oral (MeSH), Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Amantadine (administration & dosage), Amantadine (pharmacokinetics), Amantadine (therapeutic use), Delayed-Action Preparations (administration & dosage), Delayed-Action Preparations (pharmacokinetics), Delayed-Action Preparations (therapeutic use), Female (MeSH), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Parkinson Disease (drug therapy), Renal Insufficiency (metabolism), Tablets (administration & dosage), Tablets (pharmacokinetics), Tablets (therapeutic use), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Amantadine, Delayed-Action Preparations, Tablets.
- chemical , pharmacokinetics : Amantadine, Delayed-Action Preparations, Tablets.
- chemical , therapeutic use : Amantadine, Delayed-Action Preparations, Tablets.
- drug therapy : Parkinson Disease.
- metabolism : Renal Insufficiency.
- Administration, Oral, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Young Adult.
Abstract
BACKGROUND
An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson's disease and drug-induced extrapyramidal reactions in adults.
OBJECTIVES
To determine the pharmacokinetic profile of extended-release amantadine in subjects with varying degrees of renal impairment.
METHODS
Adults with normal renal function (creatinine clearance > 89 mL/min/1.73 m
RESULTS
Following a single oral dose of the 129-mg extended-release amantadine tablet, amantadine plasma concentration increased slowly, reaching a peak at approximately 11 h. Amantadine elimination was reduced in subjects with renal impairment. Renal clearance decreased from 10,965 to 2618 mL/h in subjects with severe renal impairment compared to those with normal renal function. Pharmacokinetic modeling and simulation methods were used to recommend the oral administration of 129-mg extended-release amantadine tablets at intervals of 24, 48, 72, 96, 120, or 168 h depending on the degree of renal function.
CONCLUSIONS
Renal impairment was associated with reduced amantadine clearance. Based on pharmacokinetic modeling and simulations, dose regimens were recommended for subjects with impaired renal function to provide systemic amantadine exposure similar to subjects with normal renal function taking a once-daily extended-release amantadine tablet.
DOI: 10.1007/s40263-019-00651-1
PubMed: 31342404
PubMed Central: PMC6669187
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.</title><author><name sortKey="Devries, Tina" sort="Devries, Tina" uniqKey="Devries T" first="Tina" last="Devries">Tina Devries</name><affiliation wicri:level="1"><nlm:affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807</wicri:regionArea><wicri:noRegion>08807</wicri:noRegion></affiliation></author><author><name sortKey="Dentiste, Angela" sort="Dentiste, Angela" uniqKey="Dentiste A" first="Angela" last="Dentiste">Angela Dentiste</name><affiliation wicri:level="1"><nlm:affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807</wicri:regionArea><wicri:noRegion>08807</wicri:noRegion></affiliation></author><author><name sortKey="Di Lea, Clifford" sort="Di Lea, Clifford" uniqKey="Di Lea C" first="Clifford" last="Di Lea">Clifford Di Lea</name><affiliation wicri:level="1"><nlm:affiliation>Aclairo Pharmaceutical Development Group, Inc., 1950 Old Gallows Road, Suite 300, Vienna, VA, 22182, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Aclairo Pharmaceutical Development Group, Inc., 1950 Old Gallows Road, Suite 300, Vienna, VA, 22182</wicri:regionArea><wicri:noRegion>22182</wicri:noRegion></affiliation></author><author><name sortKey="Pichette, Vincent" sort="Pichette, Vincent" uniqKey="Pichette V" first="Vincent" last="Pichette">Vincent Pichette</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Maisonneuve-Rosemont, 5415 Assumption Blvd, Montreal, QC, H1T 2M4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Hôpital Maisonneuve-Rosemont, 5415 Assumption Blvd, Montreal, QC, H1T 2M4</wicri:regionArea><wicri:noRegion>H1T 2M4</wicri:noRegion></affiliation></author><author><name sortKey="Jacobs, David" sort="Jacobs, David" uniqKey="Jacobs D" first="David" last="Jacobs">David Jacobs</name><affiliation wicri:level="1"><nlm:affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA. djacobs@osmotica.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807</wicri:regionArea><wicri:noRegion>08807</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31342404</idno><idno type="pmid">31342404</idno><idno type="doi">10.1007/s40263-019-00651-1</idno><idno type="pmc">PMC6669187</idno><idno type="wicri:Area/Main/Corpus">000060</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000060</idno><idno type="wicri:Area/Main/Curation">000060</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000060</idno><idno type="wicri:Area/Main/Exploration">000060</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.</title><author><name sortKey="Devries, Tina" sort="Devries, Tina" uniqKey="Devries T" first="Tina" last="Devries">Tina Devries</name><affiliation wicri:level="1"><nlm:affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807</wicri:regionArea><wicri:noRegion>08807</wicri:noRegion></affiliation></author><author><name sortKey="Dentiste, Angela" sort="Dentiste, Angela" uniqKey="Dentiste A" first="Angela" last="Dentiste">Angela Dentiste</name><affiliation wicri:level="1"><nlm:affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807</wicri:regionArea><wicri:noRegion>08807</wicri:noRegion></affiliation></author><author><name sortKey="Di Lea, Clifford" sort="Di Lea, Clifford" uniqKey="Di Lea C" first="Clifford" last="Di Lea">Clifford Di Lea</name><affiliation wicri:level="1"><nlm:affiliation>Aclairo Pharmaceutical Development Group, Inc., 1950 Old Gallows Road, Suite 300, Vienna, VA, 22182, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Aclairo Pharmaceutical Development Group, Inc., 1950 Old Gallows Road, Suite 300, Vienna, VA, 22182</wicri:regionArea><wicri:noRegion>22182</wicri:noRegion></affiliation></author><author><name sortKey="Pichette, Vincent" sort="Pichette, Vincent" uniqKey="Pichette V" first="Vincent" last="Pichette">Vincent Pichette</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Maisonneuve-Rosemont, 5415 Assumption Blvd, Montreal, QC, H1T 2M4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Hôpital Maisonneuve-Rosemont, 5415 Assumption Blvd, Montreal, QC, H1T 2M4</wicri:regionArea><wicri:noRegion>H1T 2M4</wicri:noRegion></affiliation></author><author><name sortKey="Jacobs, David" sort="Jacobs, David" uniqKey="Jacobs D" first="David" last="Jacobs">David Jacobs</name><affiliation wicri:level="1"><nlm:affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA. djacobs@osmotica.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807</wicri:regionArea><wicri:noRegion>08807</wicri:noRegion></affiliation></author></analytic><series><title level="j">CNS drugs</title><idno type="eISSN">1179-1934</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral (MeSH)</term><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Amantadine (administration & dosage)</term><term>Amantadine (pharmacokinetics)</term><term>Amantadine (therapeutic use)</term><term>Delayed-Action Preparations (administration & dosage)</term><term>Delayed-Action Preparations (pharmacokinetics)</term><term>Delayed-Action Preparations (therapeutic use)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Parkinson Disease (drug therapy)</term><term>Renal Insufficiency (metabolism)</term><term>Tablets (administration & dosage)</term><term>Tablets (pharmacokinetics)</term><term>Tablets (therapeutic use)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale (MeSH)</term><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Amantadine (administration et posologie)</term><term>Amantadine (pharmacocinétique)</term><term>Amantadine (usage thérapeutique)</term><term>Comprimés (administration et posologie)</term><term>Comprimés (pharmacocinétique)</term><term>Comprimés (usage thérapeutique)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Insuffisance rénale (métabolisme)</term><term>Jeune adulte (MeSH)</term><term>Maladie de Parkinson (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Préparations à action retardée (administration et posologie)</term><term>Préparations à action retardée (pharmacocinétique)</term><term>Préparations à action retardée (usage thérapeutique)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Amantadine</term><term>Delayed-Action Preparations</term><term>Tablets</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Amantadine</term><term>Delayed-Action Preparations</term><term>Tablets</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Delayed-Action Preparations</term><term>Tablets</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Amantadine</term><term>Comprimés</term><term>Préparations à action retardée</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Renal Insufficiency</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Insuffisance rénale</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Amantadine</term><term>Comprimés</term><term>Préparations à action retardée</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Parkinson</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amantadine</term><term>Comprimés</term><term>Préparations à action retardée</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson's disease and drug-induced extrapyramidal reactions in adults.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To determine the pharmacokinetic profile of extended-release amantadine in subjects with varying degrees of renal impairment.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Adults with normal renal function (creatinine clearance > 89 mL/min/1.73 m</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Following a single oral dose of the 129-mg extended-release amantadine tablet, amantadine plasma concentration increased slowly, reaching a peak at approximately 11 h. Amantadine elimination was reduced in subjects with renal impairment. Renal clearance decreased from 10,965 to 2618 mL/h in subjects with severe renal impairment compared to those with normal renal function. Pharmacokinetic modeling and simulation methods were used to recommend the oral administration of 129-mg extended-release amantadine tablets at intervals of 24, 48, 72, 96, 120, or 168 h depending on the degree of renal function.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Renal impairment was associated with reduced amantadine clearance. Based on pharmacokinetic modeling and simulations, dose regimens were recommended for subjects with impaired renal function to provide systemic amantadine exposure similar to subjects with normal renal function taking a once-daily extended-release amantadine tablet.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31342404</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1934</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>08</Month></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.</ArticleTitle><Pagination><MedlinePgn>783-789</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40263-019-00651-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson's disease and drug-induced extrapyramidal reactions in adults.</AbstractText><AbstractText Label="OBJECTIVES">To determine the pharmacokinetic profile of extended-release amantadine in subjects with varying degrees of renal impairment.</AbstractText><AbstractText Label="METHODS">Adults with normal renal function (creatinine clearance > 89 mL/min/1.73 m<sup>2</sup>), moderate renal impairment (creatinine clearance 30-59 mL/min/1.73 m<sup>2</sup>), or severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m<sup>2</sup>) received a single 129-mg dose (160 mg amantadine hydrochloride) of extended-release amantadine. Blood and urine samples for pharmacokinetic analysis were taken at scheduled intervals. A two-compartment pharmacokinetic population model was employed to determine optimum extended-release amantadine dosing in subjects with renal impairment.</AbstractText><AbstractText Label="RESULTS">Following a single oral dose of the 129-mg extended-release amantadine tablet, amantadine plasma concentration increased slowly, reaching a peak at approximately 11 h. Amantadine elimination was reduced in subjects with renal impairment. Renal clearance decreased from 10,965 to 2618 mL/h in subjects with severe renal impairment compared to those with normal renal function. Pharmacokinetic modeling and simulation methods were used to recommend the oral administration of 129-mg extended-release amantadine tablets at intervals of 24, 48, 72, 96, 120, or 168 h depending on the degree of renal function.</AbstractText><AbstractText Label="CONCLUSIONS">Renal impairment was associated with reduced amantadine clearance. Based on pharmacokinetic modeling and simulations, dose regimens were recommended for subjects with impaired renal function to provide systemic amantadine exposure similar to subjects with normal renal function taking a once-daily extended-release amantadine tablet.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>deVries</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dentiste</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Lea</LastName><ForeName>Clifford</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Aclairo Pharmaceutical Development Group, Inc., 1950 Old Gallows Road, Suite 300, Vienna, VA, 22182, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pichette</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Hôpital Maisonneuve-Rosemont, 5415 Assumption Blvd, Montreal, QC, H1T 2M4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Osmotica Pharmaceutical US LLC, 400 Crossing Boulevard, Bridgewater, NJ, 08807, USA. djacobs@osmotica.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051437" MajorTopicYN="N">Renal Insufficiency</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31342404</ArticleId><ArticleId IdType="doi">10.1007/s40263-019-00651-1</ArticleId><ArticleId IdType="pii">10.1007/s40263-019-00651-1</ArticleId><ArticleId IdType="pmc">PMC6669187</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Pharmacokinet. 2002;41(4):261-309</Citation><ArticleIdList><ArticleId IdType="pubmed">11978145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephron. 1976;16(1):31-41</Citation><ArticleIdList><ArticleId IdType="pubmed">1244564</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neurol. 2006;56(1):59-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16921246</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 1991;11(6):460-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1771145</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2007 Dec 12;2(12):e1305</Citation><ArticleIdList><ArticleId IdType="pubmed">18074029</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Emerg Med. 2009 Mar;27(3):371.e5-371.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">19328395</ArticleId></ArticleIdList></Reference><Reference><Citation>PM R. 2010 Jan;2(1):37-42</Citation><ArticleIdList><ArticleId IdType="pubmed">20129511</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurodegener Dis Manag. 2018 Apr;8(2):73-80</Citation><ArticleIdList><ArticleId IdType="pubmed">29564954</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 1988 Jan;14(1):35-51</Citation><ArticleIdList><ArticleId IdType="pubmed">3280212</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 1984;7(2):149-51</Citation><ArticleIdList><ArticleId IdType="pubmed">6733694</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Nephrol. 1982 Jan;17(1):19-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7035042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1981 Apr;94(4 pt 1):454-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7212501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1980 Jul;93(1):46-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7396313</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 1994 May;105(5):1630</Citation><ArticleIdList><ArticleId IdType="pubmed">8181395</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Suppl. 1995;46:407-13</Citation><ArticleIdList><ArticleId IdType="pubmed">8821076</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Devries, Tina" sort="Devries, Tina" uniqKey="Devries T" first="Tina" last="Devries">Tina Devries</name></noRegion><name sortKey="Dentiste, Angela" sort="Dentiste, Angela" uniqKey="Dentiste A" first="Angela" last="Dentiste">Angela Dentiste</name><name sortKey="Di Lea, Clifford" sort="Di Lea, Clifford" uniqKey="Di Lea C" first="Clifford" last="Di Lea">Clifford Di Lea</name><name sortKey="Jacobs, David" sort="Jacobs, David" uniqKey="Jacobs D" first="David" last="Jacobs">David Jacobs</name></country><country name="Canada"><noRegion><name sortKey="Pichette, Vincent" sort="Pichette, Vincent" uniqKey="Pichette V" first="Vincent" last="Pichette">Vincent Pichette</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000066 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000066 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31342404
|texte= Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31342404" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |